10-Q: NanoVibronix Reports Deepening Losses Amid Merger

NanoVibronix, Inc. reported a significant increase in net loss and declining revenues for Q2 2025, alongside a recent merger, multiple reverse stock splits, and a product withdrawal.

Summary

• NanoVibronix, Inc. completed the ENvue Merger on February 14, 2025, acquiring ENvue Medical Holdings LLC, a medical device company focused on enteral feeding.
• The company effected a 1-for-11 reverse stock split on March 13, 2025, and a 1-for-10 reverse stock split on August 11, 2025, to maintain Nasdaq listing compliance.
• Net loss for the three months ended June 30, 2025, increased by 477% to $3,971 thousand, compared to $688 thousand for the same period in 2024.
• Revenues for the three months ended June 30, 2025, decreased by 40% to $494 thousand from $817 thousand in the prior year, primarily due to reduced sales from NanoVibronix's largest distributor.
• Gross profit turned negative at $(35) thousand for Q2 2025, down from $428 thousand in Q2 2024, largely due to a $159 thousand inventory write-off and $186 thousand technology amortization.
• Operating expenses surged, with R&D increasing by 420% to $972 thousand, Selling & Marketing by 260% to $717 thousand, and G&A by 215% to $2,252 thousand, partly due to the ENvue merger and clinical trial costs.
• The company raised approximately $8.2 million in net proceeds from an underwritten public offering of Series G Convertible Preferred Stock and warrants on May 15, 2025.
• Subsequent to the quarter, on July 18, 2025, the company closed a private placement of Series H Convertible Preferred Stock and warrants, generating $8 million in gross proceeds, with potential for additional future capital raises.
• The 510(k) application for the PainShield MD Plus product was withdrawn on August 19, 2025, due to inaccuracies, leading to a halt in future sales and a $159 thousand inventory allowance.
• The company faces a $2.2 million accrued arbitration award to Protrade Systems, Inc., with an appeal decision expected later this year.
• Management identified material weaknesses in internal control over financial reporting as of June 30, 2025, and is implementing remediation efforts.

Sentiment

Score: 1

Explanation: The company faces severe financial distress, evidenced by rapidly increasing losses, declining revenue, negative gross profit, and a going concern warning. While capital has been raised, it is highly dilutive and necessary for immediate survival rather than growth. The product withdrawal and ongoing legal issues further compound the negative outlook, indicating significant operational and strategic challenges.

Positives

• Successfully completed the ENvue Merger on February 14, 2025, expanding into the enteral feeding medical device sector.
• Regained compliance with Nasdaq's Bid Price Rule and Equity Rule as of April 9, 2025, avoiding delisting, though subject to a one-year monitoring period.
• Secured significant capital through a $8.2 million net proceeds public offering of Series G Preferred Stock in May 2025.
• Raised an additional $8 million in gross proceeds from a private placement of Series H Preferred Stock and warrants in July 2025, providing crucial liquidity.
• Cash and cash equivalents increased to $4,030 thousand as of June 30, 2025, from $752 thousand at December 31, 2024, primarily due to financing activities.

Negatives

• Net loss for the three months ended June 30, 2025, significantly worsened to $(3,971) thousand from $(688) thousand in the prior year, a 477% increase.
• Revenues decreased by 40% to $494 thousand for the three months ended June 30, 2025, primarily due to reduced sales from a major distributor.
• Gross profit turned negative at $(35) thousand for Q2 2025, down from $428 thousand, with gross margin falling to -7% from 52%, impacted by a $159 thousand inventory write-off and $186 thousand technology amortization.
• Operating expenses surged across all categories: R&D increased by 420% to $972 thousand, Selling & Marketing by 260% to $717 thousand, and G&A by 215% to $2,252 thousand.
• The company has incurred recurring losses and negative cash flows from operations, with an accumulated deficit of $75,988 thousand as of June 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern for the next twelve months.
• The 510(k) application for the PainShield MD Plus product was withdrawn due to inaccuracies, leading to a halt in future sales and a $159 thousand inventory allowance.
• An accrued arbitration award of approximately $2.2 million (including interest) to Protrade Systems, Inc. remains a significant liability, with an appeal decision pending.
• Material weaknesses in internal control over financial reporting were identified as of June 30, 2025, indicating control deficiencies.
• The Series X, G, and H Preferred Stock contain anti-dilution provisions that may lead to further significant dilution for common stockholders through conversion price reductions and additional share issuances for dividends.

Risks

• Failure to comply with Nasdaq's continued listing requirements could lead to delisting, reducing stock liquidity and hindering capital raising.
• The Series X, G, and H Preferred Stock contain anti-dilution provisions that may result in significant future dilution of common stock through conversion price reductions and additional share issuances for dividends.
• The company may not have sufficient available shares to satisfy conversions of Series G and H Preferred Stock if future transactions lower the conversion price, potentially requiring an increase in authorized shares which may be time-consuming and expensive.
• Inability to pay Series G Preferred Stock dividends in cash due to legal restrictions (lack of surplus or net profits) could force payment in highly dilutive common stock.
• Failure to pay Series H Preferred Stock dividends in common stock will accrue a late fee of 15% per annum, payable in cash, which could materially affect financial condition.
• The August 2025 Reverse Stock Split may not sustainably increase the common stock price or prevent future delisting.
• The August 2025 Reverse Stock Split may decrease the liquidity of common stock and result in stockholders owning odd lots with higher transaction costs.
• The August 2025 Reverse Stock Split may lead to a decrease in overall market capitalization if the per-share price does not increase proportionally.
• The company's ability to continue as a going concern is in substantial doubt due to recurring losses and negative cash flows from operations.
• Future operations are subject to quarterly variations based on distributor ordering patterns, regulatory approvals, clinical trial timing, manufacturing efficiencies, and geopolitical conflicts.
• The withdrawal of the PainShield MD Plus product due to 510(k) inaccuracies will halt future sales, impacting revenue and requiring inventory write-downs.
• Ongoing legal proceedings, specifically the $2.2 million arbitration award to Protrade Systems, Inc., pose a significant financial and operational risk.
• Material weaknesses in internal control over financial reporting could adversely affect the company's ability to record, process, summarize, and report financial information accurately.

Future Outlook

The company expects to continue incurring net losses and negative cash flows from operations, with profitability dependent on achieving adequate revenue levels. Future operations will be funded through cash on hand, additional private and/or public offerings of debt or equity securities, or a combination thereof. The company is evaluating the impact of the One Big Beautiful Bill Act (OBBBA) on its financial statements. A decision on the Protrade arbitration appeal is expected later this year.

Management Comments

• "The Company expects to incur future net losses and its transition to profitability is dependent upon, among other things, the achievement of a level of revenues adequate to support the cost structure."
• "Until the Company achieves profitability or generates positive cash flows, it will continue to be dependent on raising additional funds to fund its operations."
• "The Company intends to fund its future operations through cash on hand, additional private and/or public offerings of debt or equity securities or a combination of the foregoing."
• "The decrease [in revenues] was due primarily attributable to reduced sales to Nanovibronix's largest distributor in 2025."
• "The consolidated results now include ENvue's revenue beginning on the date of ENvue Merger (February 14th, 2025), which mitigated some of the reduction in revenues."
• "We do not anticipate that our revenues will be impacted by inflation or changing prices in the foreseeable future."
• "The increase [in R&D expenses] was mainly due to the costs of our clinical trial test program with the University of Michigan of approximately $624 thousand and the inclusion of ENvue's operations following the ENvue Merger."
• "The increase [in Selling and Marketing expenses] was primarily due to the inclusion of ENvue's operations following the ENvue Merger."
• "The increase [in General and Administrative expenses] was primarily due the costs of professional fees incurred related to our Merger. Furthermore, the inclusion of ENvue's operations following the ENvue Merger which increased the general and administrative expenses by approximately $748 thousand."
• "Because the Company does not have sufficient resources to fund our operation for the next twelve months from the date of the issuance of these unaudited interim condensed consolidated financial statements, management has substantial doubt regarding the Company's ability to continue as a going concern."
• "The Company is unaware of any safety issue related to PainShield MD Plus, but intends to halt future sales of the product."

Industry Context

NanoVibronix operates in the medical device sector, specifically in non-invasive biological response-activating devices for wound healing and pain therapy. The recent acquisition of ENvue Medical Holdings LLC expands its reach into the enteral feeding medical equipment market. The industry is characterized by high R&D costs, regulatory hurdles (e.g., FDA 510(k) clearance), and intense competition. The company's financial struggles, including significant losses and a going concern warning, highlight the challenges faced by smaller players in this capital-intensive and highly regulated environment. The withdrawal of a product due to application inaccuracies underscores the critical importance of regulatory compliance and quality control in the medical device space.

Comparison to Industry Standards

• The company's negative gross profit margin of -7% for Q2 2025 and 22% for YTD Q2 2025 is significantly below typical medical device industry standards, which often see gross margins ranging from 60% to 80% for established products, indicating severe cost management or pricing issues.
• The substantial increase in R&D expenses (420% in Q2 2025) is common for medical device companies pursuing clinical trials (e.g., University of Michigan program), but without corresponding revenue growth or clear milestones, it raises concerns about efficient capital deployment compared to peers like Medtronic or Boston Scientific, which have robust R&D pipelines with clearer commercialization paths.
• The company's accumulated deficit of $75,988 thousand and recurring negative cash flows from operations are indicative of a pre-commercial or early-commercial stage company, but the magnitude of losses relative to revenue ($494k revenue vs. $3,971k net loss in Q2 2025) suggests a highly unsustainable burn rate compared to industry benchmarks for companies of similar size.
• The need for multiple reverse stock splits and continuous capital raises through dilutive preferred stock offerings (Series G, Series H) points to a severe lack of organic funding and market confidence, contrasting sharply with financially stable medical device companies that can fund growth through retained earnings or less dilutive debt.
• The withdrawal of the PainShield MD Plus product due to 510(k) inaccuracies is a significant regulatory setback, which is a critical failure in an industry where regulatory clearance is paramount. Established companies like Johnson & Johnson or Stryker have robust regulatory affairs departments to prevent such issues, highlighting a potential weakness in NanoVibronix's internal processes.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in an arbitration dispute with Protrade Systems, Inc., which resulted in an award against the company of $1,500 thousand for lost profits and $68 thousand for arbitration costs, totaling approximately $2.2 million including interest accrued as of June 30, 2025.
• The company filed a cross-motion to vacate the arbitration award, which was denied, and an appeal was filed with the Appellate Division, Second Department, with oral arguments presented on May 30, 2025. A decision is expected at an undetermined date later this year.

Related Party Transactions

• Aurora Cassirer, a former board member (resigned April 1, 2025), was associated with the law firm Pierson Ferdinand LLP, which has been handling the company's Protrade litigation and appeals since January 1, 2024. Pierson Ferdinand was paid $58 thousand for services during the six months ended June 30, 2025, while Ms. Cassirer was on the board.
• Alpha Capital Anstalt (Alpha) is a significant related party, involved in multiple financing arrangements:
• ENvue issued a Consolidated Secured Note (Alpha Note) for $2,497 thousand to Alpha on January 17, 2025, with a balance of $1,975 thousand as of June 30, 2025.
• The company entered into a Securities Purchase Agreement with Alpha on February 13, 2025, for a senior convertible debenture of $500 thousand, later amended to $1,300 thousand, which was repaid in full on May 19, 2025.
• ENvue issued a promissory note (April Note) for $360 thousand to Alpha on April 11, 2025, which the company guaranteed and subsequently repaid in full on May 19, 2025.
• Doron Besser and Zeev Rotstein, appointed to the Board of Directors on February 14, 2025, in connection with the ENvue Merger, entered into standard indemnification agreements with the company.

Stakeholder Impact

• **Shareholders**: Significant dilution from multiple reverse stock splits and preferred stock offerings (Series G, Series H) with anti-dilution provisions. Increased net losses and going concern warning pose substantial risk to investment value. Nasdaq monitoring period adds uncertainty.
• **Employees**: Ongoing financial instability and operational challenges, including product withdrawal, could impact job security and morale.
• **Customers**: Withdrawal of PainShield MD Plus product means discontinuation of a product line, potentially impacting customer access to that specific device.
• **Creditors**: The company's going concern warning and recurring losses indicate elevated credit risk, although recent capital raises have provided some liquidity.
• **Suppliers**: Financial instability and potential for future operational changes could affect relationships and payment terms with suppliers.

Next Steps

• Continue efforts to remediate material weaknesses in internal control over financial reporting.
• Await decision on the appeal for the Protrade Systems, Inc. arbitration award.
• Hold a meeting of stockholders to seek approval for the issuance of common stock in excess of 19.99% under Nasdaq Stock Market Rule 5635(d) related to the Series H Preferred Stock and Warrants.
• File a Resale Registration Statement as soon as reasonably practicable for the shares underlying the Series H Preferred Stock and Warrants.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on condensed consolidated financial statements.

Key Dates

Recommendation

The company's financial performance is severely deteriorating, marked by a 477% increase in net loss and a 40% decline in revenue for Q2 2025, coupled with negative gross profit. The explicit 'going concern' warning indicates a high risk of financial failure within the next year. While recent capital raises provide temporary liquidity, they are highly dilutive and merely stave off immediate collapse rather than signal a path to sustainable growth. The withdrawal of a key product (PainShield MD Plus) due to regulatory inaccuracies is a major operational and reputational blow. The ongoing $2.2 million arbitration liability further strains an already precarious balance sheet. These factors collectively point to a company facing profound and multifaceted challenges with no clear path to profitability or long-term viability, making it a strong sell for investors.

Keywords

Medical Devices, NanoVibronix, ENvue Medical, SEC Filing, 10-Q, Quarterly Report, Financial Results, Net Loss, Revenue Decline, Reverse Stock Split, Nasdaq Compliance, Capital Raise, Preferred Stock, Warrants, Going Concern, Product Withdrawal, PainShield MD Plus, Litigation, Internal Controls, Biopharmaceutical Industry, Enteral Feeding